Marstacimab, an Anti-Tissue Factor Pathway Inhibitor, in Participants with Hemophilia. or B, with and without Inhibitors: An Integrated Analysis of Safety

被引：0

作者：

Acharya, Suchitra ^{[1
]}

Matino, Davide ^{[2
]}

Mahlangu, Johnny ^{[3
,4
]}

Turich, Carrie ^{[5
]}

Hwang, Eunhee ^{[6
]}

Hinnershitz, Tina ^{[7
]}

Mefyod, Eugeny ^{[8
]}

Palladino, Andrew ^{[6
]}

Biondo, Francesca ^{[7
]}

Gould, Travis ^{[5
]}

Teeter, John ^{[7
]}

机构：

[1] Cohen Childrens Med Ctr New York, New Hyde Pk, NY USA

[2] Thrombosis & Atherosclerosis Res Inst TaARI, Hamilton, ON, Canada

[3] Univ Witwatersrand, Johannesburg, South Africa

[4] Natl Hlth Lab Serv, Johannesburg, South Africa

[5] Pfizer Inc, New York, NY USA

[6] Pfizer Inc, Collegeville, PA USA

[7] Pfizer Inc, Groton, CT USA

[8] Pfizer Inc, Smolensk, Russia

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174682

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 45 条

[1] Immunogenicity and safety of marstacimab, an anti-tissue factor pathway inhibitor, in participants with haemophilia A or B and without inhibitors
Acharya, S. S.
Taylor, C. T.
Hwang, E.
Hinnershitz, T.
Raje, S. V.
Mefyod, E.
Palladino, A.
Biondo, F.
Teeter, J.
HAEMOPHILIA, 2024, 30 : 127 - 127
[2] Efficacy and Safety of the Anti-Tissue Factor Pathway Inhibitor Marstacimab in Participants with Severe Hemophilia without Inhibitors: Results from the Phase 3 Basis Trial
Matino, Davide
Acharya, Suchitra
Palladino, Andrew
Hwang, Eunhee
McDonald, Regina
Taylor, Carrie Turich
Teeter, John
BLOOD, 2023, 142
[3] SAFETY AND EFFICACY OF THE ANTI-TISSUE FACTOR PATHWAY INHIBITOR MARSTACIMAB IN PARTICIPANTS WITH SEVERE HEMOPHILIA WITHOUT INHIBITORS: RESULTS FROM THE PHASE 3 BASIS TRIAL AND ONGOING LONG-TERM EXTENSION STUDY
Acharya, Suchitra S.
Matino, Davide
Palladino, Andrew
Hwang, Eunhee
McDonald, Regina
Taylor, Carrie Turich
Teeter, John
AMERICAN JOURNAL OF HEMATOLOGY, 2024, 100 : 4 - 4
[4] Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results
Mahlangu, Johnny
Lamas, Jose Luis
Morales, Juan Cristobal
Malan, Daniel R.
Teeter, John
Charnigo, Robert J.
Hwang, Eunhee
Arkin, Steven
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 200 (02) : 240 - 248
[5] Dose escalation of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia without inhibitors: Results from the phase 3 basis and long-term extension trials
Jimenez-Yuste, Victor
Palladino, Andrew
McDonald, Regina
McComb, Bryan
Hwang, Eunhee
Taylor, Carrie Turich
Teeter, John
HAEMOPHILIA, 2024, 30 : 92 - 93
[6] Safety of relaxing coagulation control by anti-tissue factor pathway inhibitor in hemophilia patients: Impact of tissue distribution of tissue factor
Boban, Ana
Hermans, Cedric
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (09) : 2412 - 2414
[7] Evolution of Antidrug Antibody Assays During the Development of Anti-Tissue Factor Pathway Inhibitor Monoclonal Antibody Marstacimab
Jean Donley
Darshana Jani
Tong Zhu
Yuhong Xiang
Boris Gorovits
Steven Arkin
The AAPS Journal, 25
[8] Evolution of Antidrug Antibody Assays During the Development of Anti-Tissue Factor Pathway Inhibitor Monoclonal Antibody Marstacimab
Donley, Jean
Jani, Darshana
Zhu, Tong
Xiang, Yuhong
Gorovits, Boris
Arkin, Steven
AAPS JOURNAL, 2023, 25 (05):
[9] A Novel anti-tissue factor pathway inhibitor antibody, BAY 1093884, prevents bleeding in hemophilia a mice
Koellnberger, M.
Liu, P.
Sim, D.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 951 - 951
[10] Descriptive Characterization of Bleeding Events in Participants with Severe Hemophilia Α or B without Inhibitors, Receiving Prophylactic Marstacimab Treatment
Matino, Davide
Gould, Travis
Teeter, John
Taylor, Carrie Turich
Mcdonald, Regina
Palladino, Andrew
BLOOD, 2024, 144 : 716 - 717

← 1 2 3 4 5 →